Impax Asset Management Group plc Lowers Stock Position in Repligen Corporation (NASDAQ:RGEN)

Impax Asset Management Group plc decreased its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 23.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 804,511 shares of the biotechnology company's stock after selling 247,428 shares during the quarter. Impax Asset Management Group plc owned about 1.43% of Repligen worth $101,491,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD boosted its position in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after acquiring an additional 594,189 shares during the last quarter. Groupama Asset Managment raised its stake in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after acquiring an additional 400,680 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Repligen in the 4th quarter worth $53,428,000. Finally, Raymond James Financial Inc. purchased a new position in Repligen in the 4th quarter worth $52,492,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Royal Bank Of Canada reduced their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price for the company. Finally, Canaccord Genuity Group reduced their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average price target of $172.83.

Repligen Stock Up 0.3%

Shares of RGEN stock traded up $0.40 on Friday, reaching $127.36. 208,766 shares of the stock were exchanged, compared to its average volume of 729,442. The business's 50 day moving average price is $126.70 and its 200 day moving average price is $139.87. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of -283.02, a PEG ratio of 3.65 and a beta of 1.11. Repligen Corporation has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.28 earnings per share. As a group, sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.